Biomarin Pharmaceutical Inc (BMRN)

Operating profit margin

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Operating income (ttm)	US$ in thousands	484,214	337,026	253,658	198,772	172,714	133,995	101,053	74,639	149,562	108,182	57,380	29,900	-82,341	-67,976	-70,698	-123,315	-43,440	-1,087	58,864	58,455
Revenue (ttm)	US$ in thousands	2,830,220	2,731,722	2,563,532	2,443,023	2,373,030	2,261,604	2,184,719	2,123,138	2,059,481	1,999,471	1,903,678	1,871,615	1,827,451	1,829,463	1,891,778	1,815,339	1,822,817	1,822,364	1,813,337	1,772,797
Operating profit margin		17.11%	12.34%	9.89%	8.14%	7.28%	5.92%	4.63%	3.52%	7.26%	5.41%	3.01%	1.60%	-4.51%	-3.72%	-3.74%	-6.79%	-2.38%	-0.06%	3.25%	3.30%

December 31, 2024 calculation

Operating profit margin = Operating income (ttm) ÷ Revenue (ttm)
= $484,214K ÷ $2,830,220K
= 17.11%

Biomarin Pharmaceutical Inc's operating profit margin has shown a trend of improvement from negative figures in 2020 and 2021 to positive percentages in the following years. The company's operating profit margin was notably low in 2020 and 2021, with negative percentages indicating operating losses during those periods. However, starting from March 2022, the operating profit margin began to turn positive, showing a steady increase over the subsequent quarters.

The operating profit margin improved consistently in 2022 and 2023, demonstrating the company's ability to control costs and generate higher operating profits. By the end of December 2024, Biomarin Pharmaceutical Inc's operating profit margin had reached a substantial 17.11%, indicating significant profitability from its operations. This positive trend suggests that the company's operational efficiency and financial performance have strengthened over time, potentially enhancing shareholder value and overall financial health.